Eine Phase-1-Studie mit GTX-B001 in gesunden Subjets und Patienten mit kaltem Urtikaria (CHILL-MC)
Eine randomisierte Phase 1, randomisierte, doppelblinde, placebokontrollierte, Einzelsteigerdosis-Verträglichkeit, pharmakokinetische, pharmakodynamische und vorläufige Wirksamkeitsstudie mit GTX-B001 bei gesunden Freiwilligen (Teil A) und Patienten mit kaltem induziertem Urtikaria (Teil B) (Teil B) (Teil B)
This is a first-in-human study aimed at determining the safety of a single dose of GTX-B001 in healthy participants and in people with chronic inducible urticaria.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Detaillierte Beschreibung
GTX-B001 is a humanized bispecific antibody than binds with one arm to a protein called c-Kit and with the second arm to a protein called CD203c, both expressed on mast cells.
This study is a randomized, double-bind, placebo-controlled phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of a single dose of GTX-B001 in healthy participants (Part A) and in patients with chronic inducible urticaria (cold urticaria and symptomatic dermographism) who remain symptomatic despite treatment with antihistamines (Part B). In part B, the preliminary efficacy of GTX-B001 on the signs and symptoms of chronic inducible urticaria will also be evaluated.
48 healthy participants are estimated to be enrolled in part A in five ascending cohorts, while 24 patients with chronic inducible urticaria are estimated to be enrolled in Part B in two ascending cohorts.
Potential participants will be screened for up to 4 weeks prior to enrollment. GTX-B001 will be administered intravenously on Day 1 to randomized participants who will be followed for 12 weeks post-treatment.
Participants will be required to attend a total of 9 visits including the screening visit.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
-
Berlin, Deutschland
- Rekrutierung
- Charite Universitaetsmedizin Berlin
-
Kontakt:
- Principal Investigator
- Telefonnummer: +49 30 450 518 219
- E-Mail: hautsache-ifa@charite.de
-
Berlin, Deutschland
- Aktiv, nicht rekrutierend
- Charité Research Organization gmbh
-
Halle, Deutschland
- Rekrutierung
- Dermatologische Praxis
-
Kontakt:
- Principal Investigator
- Telefonnummer: +493452082056
- E-Mail: info@hautarzthalle.de
-
Marburg, Deutschland
- Rekrutierung
- Universitaetsklinikum Giessen und Marburg GmbH
-
Kontakt:
- Principal Investigator
- Telefonnummer: +4964215862932
- E-Mail: hautklinik-marburg@uk-gm.de
-
Münster, Deutschland
- Rekrutierung
- Universitatsklinikum Münster
-
Kontakt:
- Principal Investigator
- Telefonnummer: +492518355555
- E-Mail: derma@ukmuenster.de
-
Tübingen, Deutschland
- Rekrutierung
- Universitaetsklinikum Tübingen
-
Kontakt:
- Principal Investigator
- Telefonnummer: +4970712983471
- E-Mail: studienzentrum.immundermatologie@med.uni-tuebingen.de
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Key inclusion Criteria (Part A):
- The subject is between 18 and 55 years of age (both inclusive) at the date of screening.
- The subject is in good general health based on the medical history, physical examination and the results of vital signs, electrocardiogram and clinical laboratory, as judged by the investigator.
Key inclusion Criteria (Part B):
- The subject is between 18 and 75 years of age (both inclusive) at the date of screening
- A history of signs and/or symptoms of ColdU or SD experienced ≥ 3 months prior to screening.
- For ColdU patients, a positive provocation test during screening and baseline, using the TempTest® device.
- For SD patients, a positive provocation test with at least 3 pins during screening and baseline, using the FricTest® device.
- Inadequate control of ColdU or SD by second generation H1-antihistamine (sgAH) as defined as the presence of itch and hives following a trigger (e.g. cold or scratching, respectively) within the last 6 weeks prior to screening in spite of use of a sgAH.
- A Urticaria Control Test (UCT) score of < 12 at screening.
Key exclusion Criteria (Parts A & B):
- Presence of any clinically significant illness, such as cardiovascular, neurologic, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic, immunologic, or endocrine disease or disorder that would interfere with the patient's safety or the interpretation of trial results in the judgment of the investigator.
- Treatment with an investigational drug or intervention for any condition within three months of screening, or concurrent participation in another clinical trial in which an investigational drug is administered.
- Treatment with immunomodulating therapy (e.g., intravenous or intramuscular immunoglobulins, systemic corticosteroids, cyclosporine, methotrexate, dapsone, cyclophosphamide, tacrolimus, mycophenolate mofetil, hydroxychloroquine, infliximab, adalimumab, etanercept, etc.) within 4 weeks (or 5 half-lives, whichever is longer) prior to screening.
- Use of any monoclonal antibody or therapeutic protein within 4 weeks (or 5 half-lives, whichever is longer) prior to screening.
- History of anaphylaxis, autoimmune disorders requiring more than topical medication, or asthma requiring regular use of inhaled medication within the past 5 years, unless, in the opinion of the Investigator, the condition is not considered clinically significant and is unlikely to affect subject safety or study outcomes.
Additionally for Part B:
- Disease with symptoms of urticaria or angioedema other than Chronic Urticaria (CU), for example urticaria vasculitis, erythema multiforme, mastocytosis, or drug-induced urticaria. Patients with concomitant Chronic Spontaneous Urticaria (CSU) or other forms of Chronic Inducible Urticaria (CIndU) are eligible provided that symptoms at screening are consistent with ColdU or SD and that ColdU or SD is the dominant form of CU.
- Any other skin disease associated with chronic itching that might influence in the investigators' opinion of the study evaluations and results, e.g., atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, or psoriasis.
- Receipt of any biologic therapy for urticaria control (e.g. omalizumab, dupilumab, ligelizumab, etc.) within three months of screening (whether on-label or off-label).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Part A (HV) - GTX-B001
Healthy participants will receive a single dose of GTX-B001 |
Single infusion of one of up to five dosages of GTX-B001
Andere Namen:
|
|
Placebo-Komparator: Part A (HV) - Normal Saline
Healthy participants assigned to receive placebo will receive a single dose of normal saline |
Single infusion of normal saline |
|
Experimental: Part B (ColdU/SD) - GTX-B001
Patients with cold urticaria or symptomatic dermographism will receive a single dose of GTX-B001 |
Single infusion of one of up to five dosages of GTX-B001
Andere Namen:
|
|
Placebo-Komparator: Part B (ColdU/SD) - Normal Saline
Patients with cold urticaria or symptomatic dermographism assigned to receive placebo will receive a single dose of normal saline |
Single infusion of normal saline |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety as assessed by the incidence and severity of adverse events (Parts A and B)
Zeitfenster: Day 1 to Day 85
|
Safety and tolerability of a single intravenous infusion of GTX-B001 as assessed by the percentage of subjects at each dose level with Grade 2 or higher adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE). |
Day 1 to Day 85
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
GTX-B001 pharmacokinetics (Parts A and B)
Zeitfenster: Day 1 to Day 85
|
Serum concentrations of GTX-B001 at specified visits |
Day 1 to Day 85
|
Andere Ergebnismessungen
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
GTX-B001 pharmacodynamics (Parts A and B)
Zeitfenster: Day 1 to Day 85
|
Change from baseline in blood biomarkers such as serum tryptase |
Day 1 to Day 85
|
|
GTX-B001 pharmacodynamics in skin (Part B)
Zeitfenster: Day 1 to Day 29
|
Change from baseline in mast cell density and mast cell activation markers upon cold or friction provocation, assessed from skin punch biopsy at baseline and three times post-treatment. |
Day 1 to Day 29
|
|
Evaluation of immunogenicity (Parts A and B)
Zeitfenster: Day 1 to Day 85
|
Incidence of anti-drug antibodies |
Day 1 to Day 85
|
|
Disease control (Part B ColdU) - Critical Temperature Threshold (CTT)
Zeitfenster: Day 1 to Day 85
|
Change from baseline and percentage of responders in Critical Temperature Threshold (CTT) over time as determined by provocation testing using the TempTest®. The CTT determines the highest temperature that induces symptoms. |
Day 1 to Day 85
|
|
Disease control (Part B SD) - Critical Friction Threshold (CFT)
Zeitfenster: Day 1 to Day 85
|
Change from baseline and percentage of responders in Critical Friction Threshold (CFT) over time as determined by provocation testing using the FricTest®. The CFT determines the shortest pin length (or lowest pressure) that induces symptoms. |
Day 1 to Day 85
|
|
Disease control (Part B) - Urticaria Control Test (UCT)
Zeitfenster: Day 1 to Day 85
|
Change from baseline and percentage of responders for the Urticaria Control Test (UCT). Total score ranges from 0 to 16. A score of 12 or higher indicates well-controlled chronic urticaria, while a score below 12 suggests poorly controlled disease. |
Day 1 to Day 85
|
|
Disease control (Part B ColdU) - Cold Urticaria Activity Score (Cold UAS)
Zeitfenster: Day 1 to Day 85
|
Change from baseline in Cold Urticaria Activity Score (Cold UAS). The total score ranges from 0 to 6, the higher the score the higher the disease activity. |
Day 1 to Day 85
|
|
Disease control (Part B SD) - Symptomatic Dermographism Activity Score (SDAS)
Zeitfenster: Day 1 to Day 85
|
Change from baseline in Symptomatic Dermographism Activity Score (SDAS) |
Day 1 to Day 85
|
|
Disease control (Part B ColdU) - Cold Urticaria Quality of Life Questionnaire (ColdU-QoL)
Zeitfenster: Day 1 to Day 85
|
Change from baseline in Cold Urticaria Quality of Life Questionnaire (ColdU-QoL). The total score ranges from 0 to 100, the higher the score the higher the impairment. |
Day 1 to Day 85
|
|
Disease control (Part B SD) - Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL)
Zeitfenster: Day 1 to Day 85
|
Change from baseline in Symptomatic Dermographism Quality of Life Questionnaire (SD-QoL). The total score ranges from 0 to 100, the higher the score the higher the impairment. |
Day 1 to Day 85
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Chronische Urtikaria
- Pathologische Prozesse
- Chronische Erkrankung
- Krankheitsattribute
- Erkrankungen des Immunsystems
- Überempfindlichkeit, sofort
- Überempfindlichkeit
- Hautkrankheiten, Gefäß
- Pathologische Zustände, Anzeichen und Symptome
- Haut- und Bindegewebserkrankungen
- Chronisch induzierbare Urtikaria
- Kalte Urtikaria
- Hautkrankheiten
- Urtikaria
- Familiärer Dermografismus
- Pharmazeutische Präparate
- Kristalloidlösungen
- Isotonische Lösungen
- Lösungen
- Salzlösung
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- GRN-GTXB001-001
- 2025-522126-13-00 (Ctis)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .